The News Review:

- Bloomberg.com: Investment Tools
- Czech Republic’s city of Brno’s short-term rating raised to…
- South Africa: Hefty Price Tag n Two New Cervical Cancer Vaccines
- Where funding comes from

Bloomberg.com: Investment Tools
Bloomberg – Mar 14, 2008
SURCE Kendle International Inc. CNTACT:Investors Patty Frank +1-513-763-1992 Media Lori Dorer +1-513-345-1685 both of Kendle International Inc.

Czech Republic’s city of Brno’s short-term rating raised to…
Forbes – Mar 14, 2008
The rating agency said Brno’s ‘A2′ issuer rating with a stable outlook remains unchanged. Brno is the Czech Republic’s second-largest city and is now a hub for IT as well as clinical research and development. All rights reserved.

South Africa: Hefty Price Tag n Two New Cervical Cancer Vaccines
AllAfrica.com – Mar 14, 2008
Gardasil has yet to be priced for the South African market but is likely to be set below the international benchmark of $120 a shot says MSD SA’s medical director Beverley Cowper. The jabs will not replace screening programmes for cervical cancer she says. "With the newer vaccines the cost (of development) has increased tremendously" says Glaxo director of clinical research and development Alain Brecx explaining why the shots are so expensive. A new vaccine takes 8-12 years to develop at a cost of between $500m and $800m he says declining to provide specifics on Cervarix. Developing vaccines has become more expensive in recent years because companies no longer just assess whether a vaccine provokes an immune response from the body and is safe but now also try to prove the vaccine actually works in the field. These large-scale efficacy trials can involve tens of thousands of volunteers. Both Glaxo and MSD say the government will benefit from their tiered pricing policies which see rich countries subsidising poor ones.

Where funding comes from
Queen's Journal – Mar 14, 2008
It’s a bad marriage. ”Schafer said the research’s integrity can’t survive partnership with a corporation adding that some areas of academic research important to public health—such as tobacco-related health studies climate change and food and nutrition—have demonstrated the negative effects of corporate funding. Schafer cited the history of clinical research into selective serotonin reuptake inhibitor drugs such as Prozac and Paxil as an example of the problems he sees as inherent in corporate funding of research. “The published literature didn’t reflect the research. The companies only published the research that was favourable to them. Most of the data was generated by university researchers but most of it wasn’t [publicly] available. “If there’s one place in society that should be a source of independent critical analysis it should be our universities and we’re failing.